Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2018. Refer to TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine for full guidance on NICE recommmendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | lenvatinib (Lenvima®) | ||
| Formulation | 4 mg, 10 mg capsule | ||
| Reference number | 976 | ||
| Indication | Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI) |
||
| Company | Eisai Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1817 | ||
| NMG meeting date | 06/09/2017 | ||
| AWMSG meeting date | 11/10/2017 | ||
| Date of issue | 19/10/2017 | ||
| NICE guidance | TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (external website - opens in new window) |
||